Glaukos Corporation (GKOS:NYSE) closed at $178.88 on October 23, 2026, up 1.24% on the day. The stock trades 6.6% below its 52-week high of $191.62 and 144.5% above its 52-week low of $73.16. Over the past year, it gained 139.6%. Glaukos Corporation is part of the Health Care sector (Medical/Dental Instruments).
In 252 trading sessions since October 23, 2025, GKOS closed higher on 126 days (50%). Its best day was April 30, 2026 (+22.84%) and its worst was May 22, 2026 (-13.52%). The stock moved 10% or more in a single session 4 times. It opened at least 5% above the previous day's high 3 times.
Glaukos Corporation, an ophthalmic medical technology company, focuses on the development and commercialization of products and procedures designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Inject trabecular micro-bypass stent that allows the surgeon to inject stents into various trabecular meshwork locations through a single corneal entry with the goal of achieving intraocular pressure reduction; iStent Supra suprachoroidal micro-bypass stent, which is designed to reduce intraocular pressure by accessing the suprachoroidal space in the eye; and iDose, a targeted injectable drug delivery implant that is designed to be pre-loaded into a small gauge needle and injected into the eye through a self-sealing corneal needle penetration. It markets its products through direct sales force in the United States and internationally, as well as through distribution partners in Europe, the Asia Pacific, and internationally. Glaukos Corporation was founded in 1998 and is headquartere...
Find more stocks like GKOS with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.